Competition Corner

In a marked shift toward competition-focused healthcare policy, the latest Executive Order on drug pricing reflects the Administration’s expanding use of antitrust tools to address high pharmaceutical costs. Framed around the “most-favored-nation” principle, this initiative is more than a pricing measure—it signals a broader regulatory agenda that targets market power and pricing disparities long shielded from traditional enforcement. Here’s what companies across the healthcare sector need to know.

On March 18, President Donald Trump fired the Federal Trade Commission’s two remaining Democratic commissioners, Alvaro Bedoya and Rebecca Kelly Slaughter, in an unprecedented move that will likely be litigated to the Supreme Court.